Transaction in own shares

Arix Bioscience PLC (ARIX) 
Transaction in own shares 
26-March-2021 / 17:14 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Arix Bioscience plc 
 
Transaction in own shares 
 
LONDON, 26 March 2021: Arix Bioscience plc ("Arix" or "the Company"), a global venture capital company focused on 
investing in and building breakthrough biotech companies, today announces that it purchased the following number of its 
ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a 
buyback programme announced on 22 March 2021. 
 
Date of purchase                      26 March 2021 
Aggregate number of shares purchased  78,000 
Highest price paid per share          192.00p 
Lowest price paid per share           191.50p 
Average price paid per share          191.95p 

Arix intends to retain the purchased shares in treasury.

Following settlement of the above purchase, Arix will have 135,230,653 ordinary shares of 0.001 pence each in issue (excluding 379,000 ordinary shares of 0.001 pence each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme.

[ENDS]

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

[phone]

[e-mail]

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

[phone]

[e-mail]

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

Transaction Date Transaction Time Volume Price (GBp) Platform              Transaction Reference Number 
26/03/2021       08:19:31         20,000 192.00      London Stock Exchange 00232099194TRLO0 
26/03/2021       08:36:36         25,000 192.00      London Stock Exchange 00232104491TRLO0 
26/03/2021       13:30:39         25,000 192.00      London Stock Exchange 00232165576TRLO0 
26/03/2021       16:29:55         8,000  191.50      London Stock Exchange 00232241614TRLO0 

ISIN: GB00BD045071

Category Code: MSCH

TIDM: ARIX

LEI Code: HQCXNIX43 -----------------------------------------------------------------------------------------------------------------------

ISIN:           GB00BD045071 
Category Code:  POS 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares 
Sequence No.:   96431 
EQS News ID:    1179092 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------ 
 

(END) Dow Jones Newswires

March 26, 2021 13:14 ET (17:14 GMT)